Exploration of Agonist and Antagonist Binding Sites within the Cytosolic AHR Complex Using Molecular Modeling

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor involved in metabolism, cell motility, development, and immune responses. Its dysregulation is linked to various diseases, including cancer, in which it can enhance tumor progression and suppress immune responses. High-resolution cryo-electron microscopy (cryo-EM) structures of the human cytosolic AHR complex have recently been solved and have provided insights into its agonist-binding mechanisms. However, our understanding of AHR antagonist binding remains limited. Our computational study, using the structure of the indirubin-bound human cytosolic AHR complex together with state-of-the-art docking algorithms and molecular dynamics simulations, suggests that AHR antagonists may bind either to the ligand-binding pocket or to alternative, as yet unexplored, sites outside of the ligand-binding pocket. These findings suggest novel molecular mechanisms of AHR inhibition and provide the foundation for experimental evaluation to advance our understanding of the therapeutic potential of current AHR inhibitors and to support future drug development efforts.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-03-05
DOI
https://doi.org/10.1021/acsomega.5c10598
Primary Topic
Receptor Mechanisms and Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploration of Agonist and Antagonist Binding Sites within the Cytosolic AHR Complex Using Molecular Modeling

Ahmed Sadik, Francisco Yanqui-Rivera, Christiane A. Opitz, Saskia Trump et al.
ACS Omega
Receptor Mechanisms and Signaling
article

Exploration of Agonist and Antagonist Binding Sites within the Cytosolic AHR Complex Using Molecular Modeling

Ahmed Sadik, Francisco Yanqui-Rivera, Christiane A. Opitz, Saskia Trump, Ivana Karabogdan, Deepak Sayeeram, Ute F. Röhrig, Aubry K. Miller
article en

Abstract

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor involved in metabolism, cell motility, development, and immune responses. Its dysregulation is linked to various diseases, including cancer, in which it can enhance tumor progression and suppress immune responses. High-resolution cryo-electron microscopy (cryo-EM) structures of the human cytosolic AHR complex have recently been solved and have provided insights into its agonist-binding mechanisms. However, our understanding of AHR antagonist binding remains limited. Our computational study, using the structure of the indirubin-bound human cytosolic AHR complex together with state-of-the-art docking algorithms and molecular dynamics simulations, suggests that AHR antagonists may bind either to the ligand-binding pocket or to alternative, as yet unexplored, sites outside of the ligand-binding pocket. These findings suggest novel molecular mechanisms of AHR inhibition and provide the foundation for experimental evaluation to advance our understanding of the therapeutic potential of current AHR inhibitors and to support future drug development efforts.

ACS OmegaVol. 11(10)
SIB Swiss Institute of Bioinformatics (CH), German Cancer Research Center (DE), Heidelberg University (DE), German Cancer Society (DE), National Center for Tumor Diseases (DE), Institute of Molecular Medicine (IN), DKFZ-ZMBH Alliance (DE), International Drug Development (FR), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 32%
Receptor Mechanisms and Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.